HK1094312A1 - Mechanism-based targeted pancreatic beta cell imaging - Google Patents

Mechanism-based targeted pancreatic beta cell imaging

Info

Publication number
HK1094312A1
HK1094312A1 HK06113846.3A HK06113846A HK1094312A1 HK 1094312 A1 HK1094312 A1 HK 1094312A1 HK 06113846 A HK06113846 A HK 06113846A HK 1094312 A1 HK1094312 A1 HK 1094312A1
Authority
HK
Hong Kong
Prior art keywords
beta cell
pancreatic beta
cell imaging
based targeted
targeted pancreatic
Prior art date
Application number
HK06113846.3A
Other languages
English (en)
Inventor
David J Yang
Chang-Sok Oh
Saady Kohanim
Dong-Fang Yu
Ali Azhdarinia
Jerry Bryant
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of HK1094312A1 publication Critical patent/HK1094312A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK06113846.3A 2003-09-17 2006-12-15 Mechanism-based targeted pancreatic beta cell imaging HK1094312A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50368303P 2003-09-17 2003-09-17
PCT/US2004/030374 WO2005027981A1 (en) 2003-09-17 2004-09-16 Mechanism-based targeted pancreatic beta cell imaging and therapy

Publications (1)

Publication Number Publication Date
HK1094312A1 true HK1094312A1 (en) 2007-03-30

Family

ID=34375381

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06113846.3A HK1094312A1 (en) 2003-09-17 2006-12-15 Mechanism-based targeted pancreatic beta cell imaging

Country Status (16)

Country Link
US (2) US7611693B2 (ko)
EP (2) EP1675625B1 (ko)
JP (3) JP5395327B2 (ko)
KR (2) KR101152729B1 (ko)
CN (1) CN1867363B (ko)
AU (1) AU2004273911B2 (ko)
BR (1) BRPI0414512B8 (ko)
CA (1) CA2539384C (ko)
DK (1) DK1675625T3 (ko)
ES (1) ES2403378T3 (ko)
HK (1) HK1094312A1 (ko)
IL (1) IL174374A (ko)
NO (1) NO336658B1 (ko)
PL (1) PL1675625T3 (ko)
PT (1) PT1675625E (ko)
WO (1) WO2005027981A1 (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1867363B (zh) * 2003-09-17 2010-05-12 得克萨斯大学体系董事会 用于使胰腺显像的组合物及其用途
WO2006104401A1 (en) * 2005-03-26 2006-10-05 Protemix Corporation Limited Copper antagonist compositions
AU2006266229B2 (en) * 2005-06-29 2013-02-21 The Trustees Of Columbia University In The City Of New York Use of DTBZ for imaging endocrine pancreas and beta cell mass in type 1 diabetes
WO2008038304A2 (en) * 2006-09-26 2008-04-03 Jegannathan Srinivas Therapeutical formulation comprising an alpha-glucosidase inhibitor and a nitric oxide scavenger.
WO2008038302A2 (en) * 2006-09-26 2008-04-03 Jegannathan Srinivas Therapeutic formulation comprising a sulfonylurea, metformin and a nitric oxide scavenger.
AU2008353360A1 (en) 2008-03-24 2009-10-01 The Board Of Regents Of The University Of Texas System Image-guided therapy of myocardial disease: composition, manufacturing and applications
US20120177571A1 (en) * 2009-07-31 2012-07-12 Riken Pancreatic endocrine cell indicating agent and utilization of same

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2951135A1 (de) 1979-12-19 1981-06-25 Hoechst Ag, 6230 Frankfurt Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung
JPS57102820A (en) 1980-12-19 1982-06-26 Nippon Mejifuijitsukusu Kk Agent for radiodiagnosis
JPS5944329A (ja) 1982-09-07 1984-03-12 Nippon Mejifuijitsukusu Kk 新規な放射性診断剤
JPS59193833A (ja) 1983-04-19 1984-11-02 Nippon Mejifuijitsukusu Kk 新規な二官能配位子化合物含有放射性診断剤
US4732864A (en) 1983-10-06 1988-03-22 E. I. Du Pont De Nemours And Company Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules
JPS6354321A (ja) 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
JPH01186899A (ja) 1988-01-18 1989-07-26 Nippon Mejifuijitsukusu Kk 膜透過性を有するＴｃ−９９ｍ単核錯体
MY106120A (en) * 1988-12-05 1995-03-31 Novartis Ag Peptide derivatives.
US5094837A (en) 1990-01-22 1992-03-10 Wayne State University Method for use of magnetic resonance imaging to image pancreas using secretin
US4994258A (en) 1990-03-05 1991-02-19 Merck & Co., Inc. Gamma emitting, CCK-A antagonists for pancreatic imaging
FR2661187B1 (fr) 1990-04-20 1994-08-05 Inst Nat Sante Rech Med Proteine associee a la pancreatite aiguue. moyens pour le diagnostic de la pancreatite aiguue.
JPH05186372A (ja) 1991-07-18 1993-07-27 Green Cross Corp:The 脂肪乳剤及びｍｒｉ診断用造影剤
US5463116A (en) 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them
JP3465247B2 (ja) 1992-12-28 2003-11-10 アベンティス ファーマ株式会社 動脈硬化症の予防および治療剤
US5656600A (en) * 1993-03-25 1997-08-12 Corvas International, Inc. α-ketoamide derivatives as inhibitors of thrombosis
US5879657A (en) * 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
DE4336159A1 (de) 1993-10-22 1995-04-27 Kurt Heinz Prof Dr Bauer Hochwirksame, den Wirkstoff schnell oder kontrolliert freisetzende Zubereitungsformen von Sulfonylharnstoffen und Verfahren zu deren Herstellung
US5763200A (en) * 1995-05-12 1998-06-09 Biomeasure, Incorporated Inhibition of amylin release
EP0968001B1 (en) 1997-02-03 2003-11-05 Mallinckrodt Inc. Method for the detection and localization of malignant human pancreatic tumours
WO2000023603A2 (en) 1998-10-21 2000-04-27 Arch Development Corporation Methods of treatment of type 2 diabetes
US6358491B1 (en) 1999-08-27 2002-03-19 Berlex Laboratories, Inc. Somatostatin analogs
KR20020063282A (ko) * 1999-12-28 2002-08-01 아지노모토 가부시키가이샤 경구 투여용 당뇨병 치료제
RU2281764C2 (ru) * 2000-03-17 2006-08-20 Адзиномото Ко., Инк. Лекарственные средства для лечения осложнений, связанных с диабетом, и невропатии и их применения
US20030032021A1 (en) 2000-08-21 2003-02-13 Curtis Rory A. J. 44589, a novel human ABC transporter family member and uses thereof
AU2002338572A1 (en) 2001-04-13 2002-11-11 Millennium Pharmaceuticals, Inc. 66784, a novel human potassium channel and uses therefor
CN1867363B (zh) * 2003-09-17 2010-05-12 得克萨斯大学体系董事会 用于使胰腺显像的组合物及其用途

Also Published As

Publication number Publication date
KR101152729B1 (ko) 2012-06-15
JP2007505915A (ja) 2007-03-15
PT1675625E (pt) 2013-05-23
DK1675625T3 (da) 2013-05-13
KR20110119813A (ko) 2011-11-02
EP2474328A2 (en) 2012-07-11
JP5395327B2 (ja) 2014-01-22
BRPI0414512A (pt) 2006-11-07
CA2539384A1 (en) 2005-03-31
EP1675625A4 (en) 2009-07-15
AU2004273911A1 (en) 2005-03-31
IL174374A0 (en) 2006-08-01
CN1867363B (zh) 2010-05-12
PL1675625T3 (pl) 2013-08-30
CN1867363A (zh) 2006-11-22
BRPI0414512B8 (pt) 2021-05-25
US20100278731A1 (en) 2010-11-04
EP1675625B1 (en) 2013-02-20
EP2474328A3 (en) 2012-07-18
US20050100506A1 (en) 2005-05-12
EP1675625A1 (en) 2006-07-05
WO2005027981A1 (en) 2005-03-31
ES2403378T3 (es) 2013-05-17
AU2004273911B2 (en) 2010-04-15
IL174374A (en) 2011-12-29
JP2015078223A (ja) 2015-04-23
KR20060104984A (ko) 2006-10-09
BRPI0414512B1 (pt) 2020-11-17
US7611693B2 (en) 2009-11-03
CA2539384C (en) 2012-08-28
JP2011052016A (ja) 2011-03-17
NO336658B1 (no) 2015-10-12
NO20061645L (no) 2006-04-11

Similar Documents

Publication Publication Date Title
EP1793881A4 (en) EXPANDABLE TRANSLUMINAL SHEATH
EP1819391A4 (en) EXPANDABLE TRANSLUMINAL SLAUGHTER
HK1068530A1 (en) An improved lance with two elements
EP1834505A4 (en) IMPROVED PAGING SYSTEM
HK1094312A1 (en) Mechanism-based targeted pancreatic beta cell imaging
EP1896605A4 (en) PROLIFERATION STIMULATION OF PANCREATIC LYMPHOCYTE B
HK1197310A1 (en) Smartcard-based value transfer
EP1786917A4 (en) OPTIMIZED INTERFERON BETA-GEN
GB0223424D0 (en) Disease-associated gene
EP1649000A4 (en) EXPOSURE OF PANCREATIC CELLS TO POROUS MATRICES
GB0302167D0 (en) T cell phenotype
GB0304874D0 (en) Radiation monitor
AU155971S (en) Ear thermometer
IL162558A (en) Cooled photosensitive cell
IL161302A0 (en) An audiometer
GB0300280D0 (en) Disease-associated gene
IL158173A0 (en) Nanopatch-containing cells
GB0329434D0 (en) An improved watch
AU2003904404A0 (en) Targeted marketing system
GB2402191B (en) Mobile fixing
GB2420000B (en) Pixel array
GB0313773D0 (en) Gene
GB0326598D0 (en) Gene
GB0317991D0 (en) Microrna
GB0301459D0 (en) Microrna